Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Ca... (800-930-7616 from the United States and ...)

HOME >> MEDICINE >> TECHNOLOGY

Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial

Date:11/5/2007

800-930-7616 from the United States and Canada or +1913-312-0684 internationally. The conference ID is 5441900. Please dial in approximately ten minutes prior to the start of the call. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com and clicking on the "Investor Relations" section. A replay of the webcast will be available on the Company's website for 30 days.

About Prostate Cancer

Prostate cancer is the most common noncutaneous malignancy in men and accounts for approximately 10 percent of cancer-related deaths in the United States. The American Cancer Society estimates that approximately 219,000 new cases of prostate cancer will be diagnosed in the United States, and 27,000 men will die of metastatic disease, in 2007. Prostate tumors that have stopped responding to, or are growing despite the use of, active hormone treatment strategies are characterized as hormone-refractory. Median survival in patients with hormone-refractory prostate cancer is about 10 to 18 months.

About Medivation

Medivation, Inc. is a biopharmaceutical company that acquires promising technologies in the late preclinical development phase and develops them quickly and cost-effectively. Medivation's current portfolio consists of small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company intends to build and maintain a portfolio of four to six development programs at all times. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the anticipated timing of clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigatio
'/>"/>

SOURCE Medivation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria

Post Your Comments:

(Date:3/16/2010)... Ontario , March 16 ... developer of technology and products targeting the Point-Of-Care ... that the Company has entered into a lock-up ... Yahia Gawad , pursuant to which Dr. Gawad ... the Company,s common stock held indirectly by Dr. ...

(Date:3/16/2010)... March 16 Hospitalization rates for ... thinner, dropped by approximately 30 percent when genetic ... researchers from Medco Health Solutions, Inc.-- in association ... and Mayo Clinic announced today. Results of the ... genetic testing into the management of warfarin as ...

(Date:3/16/2010)... today reported financial results for the fourth quarter and year ended December 31, 2009 . , ... , ... ... ... "ADVENTRX begins 2010 with a strong balance sheet reflecting $22.7 million in cash, taking into account ...

[0] CardioGenics Announces Lock-Up Agreement with Dr. Yahia Gawad [0] Medco, Mayo Clinic Study Reveals Using a Simple Genetic Test Reduces Hospitalization Rates by Nearly a Third for Patients on Widely Prescribed Blood Thinner [0] ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results

... Calif., Jan. 9 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... patients in a Phase 1 study to evaluate ... potent inhibitor of Janus Kinase,3 (JAK3), as a ... and other immune disorders. In preclinical studies, R348,was ...

... 8 CSG/SportsCoatings,today announced approximately 10 million square ... industry-leading antimicrobial coating, TurfAide(TM),in 2008 -- up from ... exponential increase in demand for TurfAide has been ... the Journal of the American,Medical Association that found ...

Other Medicine Technology:Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 2 Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 3 10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide 2

Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide

(Date:3/16/2010)... multiple medical problems, keeping up with countless doctor,s appointments, ... overwhelming, especially for those in challenging socioeconomic situations. ... up using the emergency room, the country,s most expensive ... kids. , But a growing concept in ... a way to simplify, organize and coordinate the complexities ...

(Date:3/16/2010)... Scientists at the University of Liverpool argue that ... health and wellbeing because they tackle the biological ... causes of overconsumption and weight gain. , Dr ... the University of Liverpool, points out that anti-obesity ... their end goal, and do not take into ...

(Date:3/16/2010)... launch of the Liebert Mobile iPhone App, a ... press releases, research, and multimedia content directly to ... biomedical, biotechnology, medicine, surgery, and nursing, integrative medicine, ... this free application. , Updated throughout the ... on the latest biotech industry news, headlines and ...

(Date:3/16/2010)... May Qualify to Receive Major Addiction Certifications at No or Low ... ... During economic times like these many students are postponing or quitting ... left by the wayside as a result. For an addict these ... fight. Today, more than ever, affordable education, especially for those with ...

(Date:3/16/2010)... went without, while 87% of younger patients got it ... Older colon cancer patients are less likely than younger ... their illness, a new study reveals. , The research ... over the age of 75 are both less likely ... chemotherapy even when they are given the treatment. , ...

Breaking Medicine News(10 mins):Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 2 Health News:Novel 'medical home' program for pediatric patients, families cuts ER visits in half 3 Health News:Anti-obesity drugs unlikely to provide lasting benefit according to scientists 2 Health News:Anti-obesity drugs unlikely to provide lasting benefit according to scientists 3 Health News:Academy's Community Initiative Offers Qualifying Former Addicts Free Vocational Training 2 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 2 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 3 Health News:Older Colon Cancer Patients Less Likely to Get Chemo 4

[0] Novel 'medical home' program for pediatric patients, families cuts ER visits in half [0] Anti-obesity drugs unlikely to provide lasting benefit according to scientists [0] Global access with Liebert mobile iPhone app [0] Academy's Community Initiative Offers Qualifying Former Addicts Free Vocational Training [0] Older Colon Cancer Patients Less Likely to Get Chemo

... say that certain compounds found in licorice have the ability ... two compounds found in plant roots that are potent inhibitors ... decay. ,This plant root is used to manufacture ... in the Feb. 24 print version of the Journal of ...

... their respective mothers, after they were swapped due to nursing error ... two women delivered surgical babies in the Ranchi Institute of Medical ... daughter at 10.30 p.m. and Meena Devi gave birth to a ... hour before I. When Savitri was shifted to my ward I ...

... cancer is the most common cancer which has been mostly ... Cancer (NSCLC) is a kind of Lung cancer// which has ... is mostly detected in the late stage of the disease ... is very less. ,Professor Mac Manus and his ...

... be as effective as it is claimed to be. Therefore ... viewed as nothing more than a waste of money according ... the above finding, several recommendations have been put across for ... Chest Physicians. According to the new guideline, published in the ...

... patients risk blindness due to lack of proper awareness according ... the Blind (RNIB).// In an attempt to prevent such a ... in the UK. ,Apart from the above-mentioned figure, ... of visual impairment in the UK. The organization has said ...

... to schizophrenia has been ruled out according to a ... link between cannabis use and impairment of mental health// ... out. It can lead to acute intoxication subsequently resulting ... was requested to examine fresh medical evidence for the ...

Other Medicine News:Health News:No Increased Schizophrenia Risk With Use Of Cannabis 2

Compounds in Licorice Can Fight Tooth Decay Mothers Happy After Exchange Of Swapped Infants Better Survival for Non-Small Cell Lung Cancer by Radiation Therapy Cough Syrups No More Effective Than Sugar Water Millions Of Diabetic And Glaucoma Patients Risk Blindness No Increased Schizophrenia Risk With Use Of Cannabis

... is the first, easy-to-use, non-invasive diagnostic ... rule-in cardiac dysfunction including acute heart ... high-risk cardiac conditions. Designed to seamlessly ... products enable clinicians caring for cardiac ...

... The Watch-PAT 100 provides a new screening, ... in the medical management of sleep-related breathing ... fulfill the unmet need for an ambulatory, ... is accessible to the great number of ...

... C-peptide of insulin is the C-terminal cleavage ... prohormone to the mature insulin molecule. Although ... it does undergo significant liver or extra-renal ... circulating half-life than insulin [1]. In addition, ...

... Testosterone, (17-Hydroxy-4-androstene-3-one), a C19 steroid, is one ... [1]. In postpubertal males, testosterone is secreted ... small amount derived from peripheral conversion of ... been estimated that over 50% of serum ...

Medicine Products:

AUDICOR® 200D Watch-PAT 100 C-Peptide of Insulin RIA Test Testosterone RIA Test

Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Ca...(800-930-7616 from the United States and ...),Health